Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis

Kidney International

Volumn 58, Issue 5, 2000, Pages 1841-1850

  Rerolle, J P ^a   Hertig, A ^a   Nguyen, G ^a   Sraer, J D ^a   Rondeau, E P ^a  

^a HÔPITAL TENON   (France)

Author keywords

Chronic glomerulonephritis; Diabetic nephropathy; Extracellular matrix; Focal segmental glomerulosclerosis; Metalloproteinase; Progressive renal lesions; Renal failure

Indexed keywords

ANGIOTENSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL MODEL; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW;

EID: 0033752717     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00355.x     Document Type: Review

References (74)

1. Molecular insights into interstitial fibrosis
2. Mesangial matrix modulation and glomerulosclerosis
3. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix
4. The renal plasminogen activating system
5. Of mice and men: The function of plasminogen activator inhibitors (PAIs) in vivo
6. Vascular development and disorders: Molecular analysis and pathogenic insights
7. Matrix metalloproteinases: Implication in vascular matrix remodelling during atherogenesis
8. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system
9. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ 3
10. Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase
11. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade
12. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells
13. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectine
14. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin
15. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells
16. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta
17. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
18. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene
19. Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticold regulation of its promoter
20. Effect of transforming growth factor-β1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells
21. Tumor necrosis factor-α increases antifibrinolytic activity of cultured human mesangial cells
22. Effect of TGF-β1 and TNF-α on the plasminogen system of rat proximal tubular epithelial cells
23. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene
24. Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells
25. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies
26. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis
27. Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits
28. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney
29. Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis
30. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator
31. Modulation of plasminogen activator inhibitor type-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
32. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure
33. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat
34. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system
35. Transforming growth factor-1 in hypertensive renal injury in Dahl salt-sensitive rats
36. Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy
37. Expression of transforming growth factor-β isoforms in human glomerular diseases
38. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy
39. Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1
40. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin- 1 in HepG2 cells
41. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
42. LPS induces major changes in the extracellular proteolytic balance in the murine kidney
43. Matrix metallo-proteinase 2 (MMP2) and MMP9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor
44. An epithelial serine protease activates the amiloride-sensitive sodium channel
45. Characterization of a plasminogen activator and its inhibitor in human mesangial cells
46. Plasminogen activator inhibitor-1 deposition in the extracellular matrix of culture human mesangial cells
47. Biology of renal cells in culture
48. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells
49. Thrombin regulates components of the fibrinolytic system in human mesangial cells
50. Perturbation of the actin cytoskeleton induces PAI-1 gene expression in cultured epithelial cells independent of substrate anchorage
51. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
52. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury
53. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis
54. Association of TGF-β signaling in angiotensin II-induced PAI-1 mRNA upregulation in mesangial cells: Role of PKC
55. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
56. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells
57. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells
58. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
59. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice
60. Effects of transforming growth factor-β1 on renal extracellular matrix components and their regulating proteins
61. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-β1
62. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis
63. Expression of TGF-beta I and matrix proteins is elevated in rats with chronic rejection
64. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells
65. High glucose-induced transforming growth factor beta 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells
66. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy
67. Association of plasminogen activator inhibitor-1, 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients
68. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
69. A laboratory model of toxin-induced hemolytic uremic syndrome
70. Inhibition of type-I plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells
71. Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells
72. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis
73. Reduced transplant arteriosclerosis in plasminogen-deficient mice
74. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure